Oral Syringes Market by Material (Glass, Plastic), End User (Clinics, Home Healthcare, Hospitals), Application, Distribution Channel - Global Forecast 2025-2032
Description
The Oral Syringes Market was valued at USD 968.44 million in 2024 and is projected to grow to USD 1,041.71 million in 2025, with a CAGR of 8.23%, reaching USD 1,823.87 million by 2032.
Comprehensive foundational overview of oral syringes capturing product purpose, safety priorities, regulatory context and end-user pathways
The following executive summary presents a concise, evidence-driven introduction to the market for oral syringes and the principal forces shaping product development, procurement, and end-user adoption. This introduction establishes the operational context by describing the core product functionality, safety considerations, and typical end-to-end pathways through which oral syringes reach clinics, hospitals, pharmacies, and home healthcare settings. With a focus on delivering clear context for decision-makers, the narrative synthesizes recent developments in design standards, sterilization protocols, and compatibility with liquid medications.
Transitioning from product fundamentals, the introduction highlights the growing importance of user-centric design-particularly dose accuracy, tamper-evident features, and ease of use for caregivers and self-administering patients. It also underscores the regulatory landscape that governs medical devices and how evolving expectations for traceability and quality assurance have influenced procurement specifications. Finally, the introduction frames the remainder of the summary by outlining the key thematic areas explored: market dynamics, trade policy impacts, segmentation-derived insights, regional differentiators, competitive behavior, and action-oriented recommendations. The aim is to equip healthcare executives, procurement leads, and product teams with a clear baseline from which to interpret subsequent analysis and to support timely strategic decisions.
How evolving materials, decentralized care models, and digital-enabled safety expectations are reshaping the oral syringes ecosystem and procurement priorities
Over recent years the landscape for oral syringes has experienced transformative shifts driven by a convergence of technological innovation, changing care delivery models, and heightened regulatory scrutiny. Innovations in polymer science and manufacturing have improved injection-molding precision and material purity, which in turn have raised expectations for dose accuracy and biocompatibility. Simultaneously, the migration of care from centralized hospitals to outpatient clinics and home settings has intensified demand for syringes that facilitate safe, repeatable dosing outside of professional supervision.
Moreover, digital health trends are beginning to intersect with consumable device procurement, as connectivity and smart dosing aids gain traction in chronic-disease management. This shift is complemented by a rising emphasis on sustainable packaging and life-cycle considerations, prompting manufacturers to explore recyclable materials and optimized supply chains. As a result, procurement teams and clinical leaders now evaluate oral syringes not only on unit cost and sterility but on user safety, environmental footprint, and compatibility with patient support technologies. Taken together, these forces are reconfiguring supplier selection criteria and product roadmaps, encouraging collaboration between clinical stakeholders, design engineers, and regulatory affairs professionals to deliver devices fit for a more decentralized and quality-conscious delivery environment.
Cumulative consequences of 2025 tariff adjustments and trade policy shifts that are driving sourcing diversification, nearshoring, and supply chain resilience strategies
Policy and trade developments implemented in 2025, particularly tariff adjustments affecting medical consumables, have produced a cumulative impact on the oral syringes supply environment. Increased import levies on select medical device components and finished goods have amplified cost pressures across the distribution chain, prompting purchasers and manufacturers to reassess sourcing strategies and production footprints. In response, some manufacturers accelerated shifts toward nearshoring and diversification of supplier bases to mitigate reliance on single-source vendors and to preserve delivery continuity.
At the same time, tighter tariffs spurred investment in domestic manufacturing capabilities where feasible, driven by a desire to reduce exposure to cross-border policy volatility and to secure faster lead times for critical healthcare supplies. Procurement teams reacted by prioritizing suppliers that could demonstrate resilient logistics, transparent cost models, and compliance with evolving trade rules. These dynamics also incentivized design modifications aimed at reducing the use of tariff-sensitive components and optimizing packaging to lower landed costs. Consequently, organizations across the value chain are increasingly balancing short-term cost management against longer-term objectives of supply security and regulatory compliance, with particular attention to documentation, customs classification, and contractual protections that guard against future policy shifts.
Segment-driven product and channel strategies demonstrating how material choice, end-user settings, application categories, and distribution channels determine design and delivery
Key segmentation insights reveal how product, channel, end-user, and application distinctions shape demand patterns and product development priorities. Based on material, the market is studied across Glass and Plastic, with glass often preferred for certain specialty formulations and plastic dominating for disposable, low-cost use cases; material selection influences sterilization approaches, breakage risk profiles, and perceptions of environmental impact. Based on end user, the market is studied across Clinics, Home Healthcare, Hospitals, and Pharmacies, where Home Healthcare is further studied across Caregiver Administered and Self Administered, and Hospitals is further studied across Private and Public; the diversity of end users drives variance in product specifications, labeling requirements, and the level of training or instructional support provided with the device.
Based on application, the market is studied across Human and Veterinary, highlighting differences in dosing scales, syringe sizing, and regulatory classification that affect design and distribution. Based on distribution channel, the market is studied across Offline Pharmacy and Online Pharmacy, with Offline Pharmacy further studied across Chain Pharmacy and Independent Pharmacy, and Online Pharmacy further studied across E-commerce Platforms and Pharmacy Websites; channel choice shapes packaging standards, replenishment cadence, and expectations for order fulfillment speed. Taken together, these segmentation axes indicate that manufacturers seeking to maximize relevance must tune product portfolios to material-based performance, end-user training needs, and channel-specific logistical constraints, while also respecting application-driven regulatory distinctions that guide labeling and quality assurance.
Regional differentiators in adoption, regulation, manufacturing capabilities, and procurement behavior that require tailored commercial and compliance strategies
Regional insights illuminate differing demand drivers, regulatory environments, and supply-chain configurations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, procurement tends to emphasize compliance with established device standards and the need for reliable domestic or nearshore supply during periods of trade uncertainty; payer dynamics and the structure of public procurement programs also influence purchasing cycles and preferred contract tenors. Conversely, Europe, Middle East & Africa presents a patchwork of regulatory regimes and cost-containment pressures that encourage standardized device portfolios and centralized quality documentation to address cross-border tenders and public health initiatives.
Meanwhile, Asia-Pacific is characterized by manufacturing scale and a vibrant supplier ecosystem, which supports rapid innovation and competitive pricing but also introduces variation in quality assurance practices that buyers must actively manage. Across all regions, localized clinical practices and differing rates of home healthcare adoption shape demand for caregiver-oriented versus self-administration solutions. In addition, regional sustainability expectations and waste-management infrastructures affect material selection and packaging strategies, prompting manufacturers and distributors to adapt offerings to suit regional compliance frameworks and logistical realities. Understanding these regional nuances is essential for companies aiming to tailor their commercial approaches and regulatory preparedness to diverse market contexts.
Competitive dynamics and provider-partner strategies revealing how innovation, quality systems, and alliances shape supplier selection and account retention
Companies competing in the oral syringes arena are differentiating through a mix of product innovation, operational excellence, and strategic partnerships. Leading manufacturers are investing in tighter tolerances, improved plunger mechanics, and advanced barrier resins to enhance dose accuracy and user confidence, while others focus on cost-efficient production techniques or specialized offerings for veterinary applications. Distribution partners and pharmacy chains play a pivotal role in shaping product accessibility, with some firms collaborating closely with pharmacy networks to pilot patient-education programs and packaging that supports safe home administration.
Strategic alliances between device makers and contract manufacturers have enabled capacity scaling and accelerated market entry for new designs, whereas certain enterprises emphasize vertical integration to exert greater control over quality and reduce exposure to external tariff shocks. At the same time, smaller niche players gain traction by addressing specific clinical needs, such as pediatric dosing or compatibility with oral formulations that require unique tip geometries. Across the competitive landscape, regulatory compliance, supplier transparency, and documented quality systems remain key differentiators that influence procurement preferences and long-term account retention. Firms that demonstrate consistent quality, responsive customer support, and the ability to adapt products to diverse clinical workflows are better positioned to capture recurring demand and to secure preferred-supplier status with institutional buyers.
Practical strategic actions manufacturers, distributors, and procurement teams can take to enhance resilience, quality, and adoption across care settings
Industry leaders should pursue a set of actionable strategies to strengthen market position, safeguard supply continuity, and accelerate adoption. Manufacturers should prioritize modular design approaches that allow rapid adjustments to materials and packaging to respond to tariff shifts and regional regulatory requirements, while simultaneously investing in process controls that enhance dose accuracy and reduce variability. Suppliers and contract manufacturers ought to establish multi-source procurement frameworks and geographically diversified capacity to minimize disruption from trade policy changes, and to develop transparent traceability mechanisms that simplify customs classification and compliance.
Meanwhile, distributors and pharmacies can improve patient outcomes and differentiation by integrating instructional content and adherence support into packaging and digital channels, thereby reducing misuse and improving satisfaction. Clinical stakeholders and purchasing groups should embed robust vendor qualification processes that weigh quality-system documentation, supply resilience, and post-market surveillance capabilities alongside price. Lastly, organizations seeking to influence policy or encourage harmonization should engage proactively with regulators and standards bodies to advocate for pragmatic requirements that balance patient safety with manufacturing feasibility. By implementing these measures, stakeholders can reduce operational risk, protect margins, and support safer, more reliable access to oral dosing devices across care settings.
A mixed-methods research approach combining stakeholder interviews, secondary regulatory synthesis, and validation steps to produce actionable and defensible insights
The research underpinning this report combined structured qualitative inquiry with rigorous secondary synthesis to ensure robust, triangulated findings. Primary data collection included interviews with clinicians, procurement officers, supply-chain managers, and regulatory affairs specialists to capture operational realities, user experiences, and decision criteria across different end-user contexts. These insights were augmented by supplier and distributor interviews to understand manufacturing constraints, logistics considerations, and responses to recent policy changes.
Secondary analysis synthesized public regulatory documents, industry guidance, and technical literature to map standards and quality expectations. The methodology also incorporated comparative case studies of supply-chain adaptations following tariff adjustments to identify practical mitigation strategies and to evaluate outcomes. Data validation procedures included cross-referencing interview claims with documented product specifications and publicly available regulatory filings, while internal peer review and expert validation sessions were used to reduce bias and ensure findings are actionable. Limitations are acknowledged in the report, including variability in regional data granularity and the rapidly evolving nature of trade policy, and these are addressed through transparency in assumptions and a recommendation for ongoing monitoring and targeted updates as new information emerges.
Synthesis of the strategic imperatives and operational priorities that position organizations to deliver safer dosing, maintain supply continuity, and win in shifting markets
In conclusion, the oral syringes landscape is being remade by material innovation, changing care delivery models, evolving distribution channels, and trade-policy dynamics that together create both challenges and opportunities for stakeholders. Manufacturers that combine design agility with rigorous quality systems, and that invest in diversified supply chains, will be better placed to meet the needs of clinics, hospitals, home-care settings, and pharmacies. Similarly, distributors and pharmacy networks that enhance patient support and streamline fulfillment can improve adherence and strengthen customer relationships.
Regional variations in regulation, procurement practice, and manufacturing capability necessitate tailored commercial and compliance strategies, while the cumulative effects of tariff changes underscore the importance of near-term tactical adjustments alongside longer-term investments in resilience. Ultimately, organizations that align product development, regulatory readiness, and procurement strategies with end-user realities will be positioned to deliver safer dosing, reduce operational risk, and capture durable value as care continues to evolve.
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive foundational overview of oral syringes capturing product purpose, safety priorities, regulatory context and end-user pathways
The following executive summary presents a concise, evidence-driven introduction to the market for oral syringes and the principal forces shaping product development, procurement, and end-user adoption. This introduction establishes the operational context by describing the core product functionality, safety considerations, and typical end-to-end pathways through which oral syringes reach clinics, hospitals, pharmacies, and home healthcare settings. With a focus on delivering clear context for decision-makers, the narrative synthesizes recent developments in design standards, sterilization protocols, and compatibility with liquid medications.
Transitioning from product fundamentals, the introduction highlights the growing importance of user-centric design-particularly dose accuracy, tamper-evident features, and ease of use for caregivers and self-administering patients. It also underscores the regulatory landscape that governs medical devices and how evolving expectations for traceability and quality assurance have influenced procurement specifications. Finally, the introduction frames the remainder of the summary by outlining the key thematic areas explored: market dynamics, trade policy impacts, segmentation-derived insights, regional differentiators, competitive behavior, and action-oriented recommendations. The aim is to equip healthcare executives, procurement leads, and product teams with a clear baseline from which to interpret subsequent analysis and to support timely strategic decisions.
How evolving materials, decentralized care models, and digital-enabled safety expectations are reshaping the oral syringes ecosystem and procurement priorities
Over recent years the landscape for oral syringes has experienced transformative shifts driven by a convergence of technological innovation, changing care delivery models, and heightened regulatory scrutiny. Innovations in polymer science and manufacturing have improved injection-molding precision and material purity, which in turn have raised expectations for dose accuracy and biocompatibility. Simultaneously, the migration of care from centralized hospitals to outpatient clinics and home settings has intensified demand for syringes that facilitate safe, repeatable dosing outside of professional supervision.
Moreover, digital health trends are beginning to intersect with consumable device procurement, as connectivity and smart dosing aids gain traction in chronic-disease management. This shift is complemented by a rising emphasis on sustainable packaging and life-cycle considerations, prompting manufacturers to explore recyclable materials and optimized supply chains. As a result, procurement teams and clinical leaders now evaluate oral syringes not only on unit cost and sterility but on user safety, environmental footprint, and compatibility with patient support technologies. Taken together, these forces are reconfiguring supplier selection criteria and product roadmaps, encouraging collaboration between clinical stakeholders, design engineers, and regulatory affairs professionals to deliver devices fit for a more decentralized and quality-conscious delivery environment.
Cumulative consequences of 2025 tariff adjustments and trade policy shifts that are driving sourcing diversification, nearshoring, and supply chain resilience strategies
Policy and trade developments implemented in 2025, particularly tariff adjustments affecting medical consumables, have produced a cumulative impact on the oral syringes supply environment. Increased import levies on select medical device components and finished goods have amplified cost pressures across the distribution chain, prompting purchasers and manufacturers to reassess sourcing strategies and production footprints. In response, some manufacturers accelerated shifts toward nearshoring and diversification of supplier bases to mitigate reliance on single-source vendors and to preserve delivery continuity.
At the same time, tighter tariffs spurred investment in domestic manufacturing capabilities where feasible, driven by a desire to reduce exposure to cross-border policy volatility and to secure faster lead times for critical healthcare supplies. Procurement teams reacted by prioritizing suppliers that could demonstrate resilient logistics, transparent cost models, and compliance with evolving trade rules. These dynamics also incentivized design modifications aimed at reducing the use of tariff-sensitive components and optimizing packaging to lower landed costs. Consequently, organizations across the value chain are increasingly balancing short-term cost management against longer-term objectives of supply security and regulatory compliance, with particular attention to documentation, customs classification, and contractual protections that guard against future policy shifts.
Segment-driven product and channel strategies demonstrating how material choice, end-user settings, application categories, and distribution channels determine design and delivery
Key segmentation insights reveal how product, channel, end-user, and application distinctions shape demand patterns and product development priorities. Based on material, the market is studied across Glass and Plastic, with glass often preferred for certain specialty formulations and plastic dominating for disposable, low-cost use cases; material selection influences sterilization approaches, breakage risk profiles, and perceptions of environmental impact. Based on end user, the market is studied across Clinics, Home Healthcare, Hospitals, and Pharmacies, where Home Healthcare is further studied across Caregiver Administered and Self Administered, and Hospitals is further studied across Private and Public; the diversity of end users drives variance in product specifications, labeling requirements, and the level of training or instructional support provided with the device.
Based on application, the market is studied across Human and Veterinary, highlighting differences in dosing scales, syringe sizing, and regulatory classification that affect design and distribution. Based on distribution channel, the market is studied across Offline Pharmacy and Online Pharmacy, with Offline Pharmacy further studied across Chain Pharmacy and Independent Pharmacy, and Online Pharmacy further studied across E-commerce Platforms and Pharmacy Websites; channel choice shapes packaging standards, replenishment cadence, and expectations for order fulfillment speed. Taken together, these segmentation axes indicate that manufacturers seeking to maximize relevance must tune product portfolios to material-based performance, end-user training needs, and channel-specific logistical constraints, while also respecting application-driven regulatory distinctions that guide labeling and quality assurance.
Regional differentiators in adoption, regulation, manufacturing capabilities, and procurement behavior that require tailored commercial and compliance strategies
Regional insights illuminate differing demand drivers, regulatory environments, and supply-chain configurations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, procurement tends to emphasize compliance with established device standards and the need for reliable domestic or nearshore supply during periods of trade uncertainty; payer dynamics and the structure of public procurement programs also influence purchasing cycles and preferred contract tenors. Conversely, Europe, Middle East & Africa presents a patchwork of regulatory regimes and cost-containment pressures that encourage standardized device portfolios and centralized quality documentation to address cross-border tenders and public health initiatives.
Meanwhile, Asia-Pacific is characterized by manufacturing scale and a vibrant supplier ecosystem, which supports rapid innovation and competitive pricing but also introduces variation in quality assurance practices that buyers must actively manage. Across all regions, localized clinical practices and differing rates of home healthcare adoption shape demand for caregiver-oriented versus self-administration solutions. In addition, regional sustainability expectations and waste-management infrastructures affect material selection and packaging strategies, prompting manufacturers and distributors to adapt offerings to suit regional compliance frameworks and logistical realities. Understanding these regional nuances is essential for companies aiming to tailor their commercial approaches and regulatory preparedness to diverse market contexts.
Competitive dynamics and provider-partner strategies revealing how innovation, quality systems, and alliances shape supplier selection and account retention
Companies competing in the oral syringes arena are differentiating through a mix of product innovation, operational excellence, and strategic partnerships. Leading manufacturers are investing in tighter tolerances, improved plunger mechanics, and advanced barrier resins to enhance dose accuracy and user confidence, while others focus on cost-efficient production techniques or specialized offerings for veterinary applications. Distribution partners and pharmacy chains play a pivotal role in shaping product accessibility, with some firms collaborating closely with pharmacy networks to pilot patient-education programs and packaging that supports safe home administration.
Strategic alliances between device makers and contract manufacturers have enabled capacity scaling and accelerated market entry for new designs, whereas certain enterprises emphasize vertical integration to exert greater control over quality and reduce exposure to external tariff shocks. At the same time, smaller niche players gain traction by addressing specific clinical needs, such as pediatric dosing or compatibility with oral formulations that require unique tip geometries. Across the competitive landscape, regulatory compliance, supplier transparency, and documented quality systems remain key differentiators that influence procurement preferences and long-term account retention. Firms that demonstrate consistent quality, responsive customer support, and the ability to adapt products to diverse clinical workflows are better positioned to capture recurring demand and to secure preferred-supplier status with institutional buyers.
Practical strategic actions manufacturers, distributors, and procurement teams can take to enhance resilience, quality, and adoption across care settings
Industry leaders should pursue a set of actionable strategies to strengthen market position, safeguard supply continuity, and accelerate adoption. Manufacturers should prioritize modular design approaches that allow rapid adjustments to materials and packaging to respond to tariff shifts and regional regulatory requirements, while simultaneously investing in process controls that enhance dose accuracy and reduce variability. Suppliers and contract manufacturers ought to establish multi-source procurement frameworks and geographically diversified capacity to minimize disruption from trade policy changes, and to develop transparent traceability mechanisms that simplify customs classification and compliance.
Meanwhile, distributors and pharmacies can improve patient outcomes and differentiation by integrating instructional content and adherence support into packaging and digital channels, thereby reducing misuse and improving satisfaction. Clinical stakeholders and purchasing groups should embed robust vendor qualification processes that weigh quality-system documentation, supply resilience, and post-market surveillance capabilities alongside price. Lastly, organizations seeking to influence policy or encourage harmonization should engage proactively with regulators and standards bodies to advocate for pragmatic requirements that balance patient safety with manufacturing feasibility. By implementing these measures, stakeholders can reduce operational risk, protect margins, and support safer, more reliable access to oral dosing devices across care settings.
A mixed-methods research approach combining stakeholder interviews, secondary regulatory synthesis, and validation steps to produce actionable and defensible insights
The research underpinning this report combined structured qualitative inquiry with rigorous secondary synthesis to ensure robust, triangulated findings. Primary data collection included interviews with clinicians, procurement officers, supply-chain managers, and regulatory affairs specialists to capture operational realities, user experiences, and decision criteria across different end-user contexts. These insights were augmented by supplier and distributor interviews to understand manufacturing constraints, logistics considerations, and responses to recent policy changes.
Secondary analysis synthesized public regulatory documents, industry guidance, and technical literature to map standards and quality expectations. The methodology also incorporated comparative case studies of supply-chain adaptations following tariff adjustments to identify practical mitigation strategies and to evaluate outcomes. Data validation procedures included cross-referencing interview claims with documented product specifications and publicly available regulatory filings, while internal peer review and expert validation sessions were used to reduce bias and ensure findings are actionable. Limitations are acknowledged in the report, including variability in regional data granularity and the rapidly evolving nature of trade policy, and these are addressed through transparency in assumptions and a recommendation for ongoing monitoring and targeted updates as new information emerges.
Synthesis of the strategic imperatives and operational priorities that position organizations to deliver safer dosing, maintain supply continuity, and win in shifting markets
In conclusion, the oral syringes landscape is being remade by material innovation, changing care delivery models, evolving distribution channels, and trade-policy dynamics that together create both challenges and opportunities for stakeholders. Manufacturers that combine design agility with rigorous quality systems, and that invest in diversified supply chains, will be better placed to meet the needs of clinics, hospitals, home-care settings, and pharmacies. Similarly, distributors and pharmacy networks that enhance patient support and streamline fulfillment can improve adherence and strengthen customer relationships.
Regional variations in regulation, procurement practice, and manufacturing capability necessitate tailored commercial and compliance strategies, while the cumulative effects of tariff changes underscore the importance of near-term tactical adjustments alongside longer-term investments in resilience. Ultimately, organizations that align product development, regulatory readiness, and procurement strategies with end-user realities will be positioned to deliver safer dosing, reduce operational risk, and capture durable value as care continues to evolve.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of safety mechanisms into oral syringes to prevent accidental injection and ensure precise dosing
- 5.2. Rising adoption of prefilled oral syringe packaging solutions to improve dosing accuracy in pediatric and geriatric populations
- 5.3. Increasing demand for eco-friendly and biodegradable oral syringe materials driven by global sustainability regulations
- 5.4. Development of color-coded and graduated oral syringes to enhance patient compliance and minimize dosing errors
- 5.5. Expansion of telehealth-driven home drug administration boosting digital sales of oral syringe delivery systems
- 5.6. Advancements in ergonomic syringe tip designs reducing oropharyngeal discomfort during pediatric medication administration
- 5.7. Partnerships between pharmaceutical firms and device manufacturers to co-develop drug-specific oral syringe platforms
- 5.8. Integration of serialization and traceability features in oral syringe packaging for enhanced regulatory compliance
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Oral Syringes Market, by Material
- 8.1. Glass
- 8.2. Plastic
- 9. Oral Syringes Market, by End User
- 9.1. Clinics
- 9.2. Home Healthcare
- 9.2.1. Caregiver Administered
- 9.2.2. Self Administered
- 9.3. Hospitals
- 9.3.1. Private
- 9.3.2. Public
- 9.4. Pharmacies
- 10. Oral Syringes Market, by Application
- 10.1. Human
- 10.2. Veterinary
- 11. Oral Syringes Market, by Distribution Channel
- 11.1. Offline Pharmacy
- 11.1.1. Chain Pharmacy
- 11.1.2. Independent Pharmacy
- 11.2. Online Pharmacy
- 11.2.1. E-commerce Platforms
- 11.2.2. Pharmacy Websites
- 12. Oral Syringes Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Oral Syringes Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Oral Syringes Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Amsino International, Inc.
- 15.3.2. AptarGroup, Inc.
- 15.3.3. B. Braun Melsungen AG
- 15.3.4. Becton, Dickinson and Company
- 15.3.5. Cardinal Health, Inc.
- 15.3.6. Gerresheimer AG
- 15.3.7. ICU Medical, Inc.
- 15.3.8. Kindly (KDL) Group
- 15.3.9. Medisafe UK Ltd
- 15.3.10. Medline Industries, LP
- 15.3.11. Nemera SA
- 15.3.12. Nipro Corporation
- 15.3.13. Owen Mumford Ltd.
- 15.3.14. Retractable Technologies, Inc.
- 15.3.15. SCHOTT AG
- 15.3.16. West Pharmaceutical Services, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
